华特达因：子公司签署褪黑素颗粒（曼乐静）总经销合同

Core Viewpoint - The company Huate Dain (000915.SZ) has reached an agreement with Japan's Nobel Pharma Co., Ltd. for the exclusive distribution of melatonin granules (Manlejing®) in mainland China, marking a significant development in the pediatric sleep disorder treatment market [1] Company Summary - Huate Dain's subsidiary, Beijing Dain Kangjian, will serve as the exclusive distributor for the melatonin product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market launch in China by July 2025 [1] - Manlejing® is the first melatonin formulation approved in China for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] - This product represents the first instance of a melatonin-based substance receiving marketing authorization as a pharmaceutical in China [1]